

10/589,995

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:06:04 ON 18 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Sep 2008 VOL 149 ISS 12

FILE LAST UPDATED: 17 Sep 2008 (20080917/ED)


Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 114 SEA FILE=REGISTRY SSS FUL L1

L4 4 SEA FILE=CAPLUS L3

=> d l4 1-4 ibib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1176376 CAPLUS

DOCUMENT NUMBER: 147:486429

TITLE: Preparation of indazole compounds that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase

INVENTOR(S): Ericsson, Anna M.; Burchat, Andrew; Frank, Kristine E.; Calderwood, David J.; Abbott, Lily K.; Argiriadi, Maria A.; Borhani, David W.; Cusack, Kevin P.; Dixon, Richard W.; Gordon, Thomas D.; Mullen, Kelly D.; Talanian, Robert V.; Wu, Xiaoyun; Zhang, Xiaolei;

Wang, Lu X.; Li, Biqin; Barberis, Claude E.; Wishart, Neil
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 266pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117465	A2	20071018	WO 2007-US8307	20070402
WO 2007117465	A3	20080828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070282101	A1	20071206	US 2007-731950	20070402
PRIORITY APPLN. INFO.:			US 2006-788553P	P 20060331
OTHER SOURCE(S):	MARPAT 147:486429			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title indazoles I [R1 = H, benzyl substituted with OMe, (un)substituted alkyl, etc.; R3 = H, halo, NH2, OH, etc.; R4 = H or NH2; R5 = H, NH2, NO2, halo, etc.; R6 = H, alkoxy, alkyl, benzo[b]thienyl, etc.; R7 = H, halo, NH2, alkenyl, etc.] that inhibit one or more receptor, or non-receptor, tyrosine or S/T kinase, were prepared and formulated. Thus, reacting thiocarbamate II with 2-(pyridin-2-yl)ethylamine afforded 39% III. The exemplified compds. I inhibit either COT or MK2 at concns. of 50 μ M or below.

IT 953404-18-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indazoles that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase)


RN 953404-18-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(7-benzo[b]thien-2-yl-1H-indazol-5-yl)-1,6-dihydro-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 953404-17-6

CMF C21 H14 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1324379 CAPLUS

DOCUMENT NUMBER: 146:220118

TITLE: Development of Dihydropyridone Indazole Amides as

Selective Rho-Kinase Inhibitors

AUTHOR(S): Goodman, Krista B.; Cui, Haifeng; Dowdell, Sarah E.; Gaitanopoulos, Dimitri E.; Ivy, Robert L.; Sehon, Clark A.; Stavenger, Robert A.; Wang, Gren Z.; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Semus, Simon F.; Evans, Christopher; Fries, Harvey E.; Jolivet, Larry J.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Bentley, Ross; Doe, Christopher P.; Hu, Erding; Lee, Dennis

CORPORATE SOURCE: Departments of Medicinal Chemistry, Biology, and Drug Metabolism and Pharmacokinetics, Cardiovascular and Urological Center of Excellence in Drug Discovery, Departments of Computational, Analytical, and Structural Sciences, Gene Expression and Protein Biochemistry, High Throughput Chemistry, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(1), 6-9
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:220118

AB Rho kinase (ROCK1) mediates vascular smooth muscle contraction and is a potential target for the treatment of hypertension and related disorders. Indazole amide 3 was identified as a potent and selective ROCK1 inhibitor but possessed poor oral bioavailability. Optimization of this lead resulted in the discovery of a series of dihydropyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead. Indazole substitution played a critical role in decreasing clearance and

improving oral bioavailability.


IT 864082-25-7P 864082-44-0P 864082-47-3P

864082-48-4P 924294-57-5P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (development of oral dihydropyridone indazole amides as selective
 rho-kinase inhibitors)


RN 864082-25-7 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-fluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-
 5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-44-0 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-
 5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-47-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-
 methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-48-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 924294-57-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 864082-23-5P 864082-32-6P 864082-35-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(development of oral dihydropyridone indazole amides as selective rho-kinase inhibitors)

RN 864082-23-5 CAPLUS


CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-4-(2-

naphthalenyl)-6-oxo- (CA INDEX NAME)




RN 864082-32-6 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864082-35-9 CAPLUS

CN 3-Pyridinecarboxamide, 4-(3,4-dichlorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:979641 CAPLUS

DOCUMENT NUMBER: 143:286421


TITLE: Preparation of amido-substituted indazoles as
Rho-kinase inhibitors

INVENTOR(S): Lee, Dennis; Goodman, Krista B.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082890	A1	20050909	WO 2005-US5345	20050218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1718638	A1	20061108	EP 2005-723356	20050218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007523186	T	20070816	JP 2006-554256	20050218
US 20080058384	A1	20080306	US 2006-589995	20060818
PRIORITY APPLN. INFO.:			US 2004-546160P	P 20040220
			WO 2005-US5345	W 20050218

OTHER SOURCE(S): MARPAT 143:286421

GI



I

AB Title compds. I [R1-2 = H, alkyl, etc.; R3 = alkyl, alkenyl, alkynyl, etc.; R4-5 = ring; R6 = Cl, F, H; R7-8 = H, halo, alkyl] are prepared. For instance, N-(1H-Indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide is prepared in 3 steps from 2,2-dimethyl-1,3-dioxane-4,6-dione, Me acetoacetate, 2-naphthaldehyde and 1H-indazol-5-amine. Compds. of the invention were active inhibitors of ROCK 1 kinase at concns. in the range of 10 μ M to 0.8 nM. I are useful in the treatment of, e.g., hypertension and tumor metastasis.

IT 864082-23-5P, N-(1H-Indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-25-7P, 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-

pyridinecarboxamide 864082-27-9P, 4-(4-Chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-30-4P, 4-(4-Chlorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-32-6P, N-(1H-Indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-34-8P, 4-(4-Biphenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-35-9P, 4-(3,4-Dichlorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-36-0P, 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-37-1P, N-(1H-Indazol-5-yl)-2-methyl-6-oxo-4-(3-quinolinyl)-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-38-2P, 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-40-6P, N-(3-Chloro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-41-7P, N-(3-Chloro-1H-indazol-5-yl)-4-(4-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-42-8P, N-(3-Chloro-1H-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-43-9P, 4-(4-Chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-44-0P, 2-Methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-45-1P, N-(3-Bromo-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-46-2P, N-(3-Ethyl-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-47-3P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-48-4P, N-(7-Chloro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-50-8P, 2-Methyl-N-(7-methyl-1H-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-51-9P, N-(3-Chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-54-2P, N-(3-Bromo-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-55-3P, 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-56-4P, N-(3-Ethyl-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-57-5P, N-(6-Fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-58-6P, 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methyl-N-(7-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-59-7P, N-(7-Chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-60-0P, 4-(4-Chloro-2-fluorophenyl)-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-61-1P, N-(3-Bromo-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-62-2P, 4-(4-Chloro-2-fluorophenyl)-N-(3-ethyl-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-63-3P, 4-(4-Chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-64-4P, 4-(4-Chloro-2-fluorophenyl)-2-methyl-N-(7-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-65-5P, 4-(4-Chloro-2-fluorophenyl)-N-(7-chloro-1H-indazol-5-yl)-2-methyl-6-oxo-

1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-66-6P,
N-(3-Bromo-1H-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-67-7P,
2-Methyl-N-(3-methyl-1H-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-68-8P,
N-(3-Ethyl-1H-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-69-9P,
2-Methyl-N-(7-methyl-1H-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-70-2P,
N-(7-Chloro-1H-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-71-3P,
N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-74-6P,
4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-75-7P,
N-(1H-Indazol-5-yl)-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-78-0P,
4-(3-Hydroxyphenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-79-1P, 4-[4-(Aminosulfonyl)phenyl]-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-80-4P, 4-(4-Cyanophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-81-5P, N-(6-Fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-84-8P, 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-85-9P,
N-(3-Chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-86-0P, 4-(4-Chloro-2-fluorophenyl)-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-89-3P, 4-(4-Chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-90-6P, 4-(4-Chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-91-7P, N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-92-8P, N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-93-9P, N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chlorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-94-0P, 4-(4-Chlorophenyl)-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-95-1P, N-(6-Chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-96-2P, 4-(4-Chlorophenyl)-N-(1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864082-99-5P, 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-(1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-00-1P, 4-(4-Chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-01-2P, N-(3-Chloro-1H-indazol-5-yl)-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-02-3P, N-(6-Fluoro-1H-indazol-5-yl)-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-03-4P, 4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-04-5P, 4-(4-Chlorophenyl)-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-05-6P, N-(6-Fluoro-1H-indazol-5-yl)-4-(2-fluoro-5-


methoxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-07-8P, N-(6-Fluoro-1H-indazol-5-yl)-4-(2-fluoro-3-methoxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-08-9P, 4-(2-Fluoro-5-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-09-0P, 4-(2-Fluoro-3-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-10-3P, 4-[5-(Aminosulfonyl)-4-chloro-2-fluorophenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-13-6P, 4-[3-(Aminosulfonyl)-4-chlorophenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-14-7P, 4-[3-(Aminosulfonyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-15-8P, 4-(2,3-Difluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-18-1P, 4-(2,3-Difluorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-19-2P, 4-(2,4-Difluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-20-5P, 4-(2,4-Difluorophenyl)-N-(1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-21-6P, N-(6-Fluoro-1H-indazol-5-yl)-4-(3-hydroxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-22-7P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-4-[3-[(methylsulfonyl)amino]phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-23-8P, 4-(4-Chloro-3-nitrophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-25-0P, 4-(3-Amino-4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-26-1P, 4-[4-Chloro-3-[(methylsulfonyl)amino]phenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-27-2P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-4-[3-nitro-4-(trifluoromethyl)phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-30-7P, 4-[3-Amino-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-31-8P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-4-[3-[(methylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-32-9P, 4-[3-[(Ethylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-33-0P, N-(6-Fluoro-1H-indazol-5-yl)-4-(2-fluoro-5-nitrophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-34-1P, N-(6-Fluoro-1H-indazol-5-yl)-4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-35-2P, 4-[2,3-Difluoro-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-36-3P, N-(6-Fluoro-1H-indazol-5-yl)-4-[3-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-37-4P, 4-(4-Cyanophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-38-5P, 4-(1,1'-Biphenyl-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-39-6P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(2-thienyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-40-9P, 4-(4-Bromophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-41-0P, 4-(5-Cyano-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-42-1P,

N-(6-Fluoro-1H-indazol-5-yl)-4-(2-fluoro-4-methoxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-43-2P,
 N-(3-Chloro-1H-indazol-5-yl)-4-(4-chloro-3-methoxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-46-5P,
 N-(3-Bromo-1H-indazol-5-yl)-4-(4-chloro-3-methoxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-47-6P,
 4-(4-Chloro-3-methoxyphenyl)-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-48-7P,
 4-(4-Chloro-3-methoxyphenyl)-N-(3-ethyl-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-49-8P,
 4-(4-Chloro-3-methoxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-50-1P,
 4-(4-Chloro-3-hydroxyphenyl)-N-(3-chloro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-51-2P,
 N-(3-Bromo-1H-indazol-5-yl)-4-(4-chloro-3-hydroxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-52-3P,
 4-(4-Chloro-3-hydroxyphenyl)-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-53-4P,
 4-(4-Chloro-3-hydroxyphenyl)-N-(3-ethyl-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-54-5P,
 4-(4-Chloro-3-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-55-6P,
 N-(3-Chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-56-7P,
 N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-1-[(3-methoxyphenyl)methyl]-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-59-0P, 1-Ethyl-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-62-5P, N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-1-(2-methylpropyl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide 864083-65-8P, 1-[2-(Dimethylamino)-2-oxoethyl]-N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amido-substituted indazoles as Rho-kinase inhibitors)

RN 864082-23-5 CAPLUS


CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)



RN 864082-25-7 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-fluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-27-9 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-30-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-32-6 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-34-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-[1,1'-biphenyl]-4-yl-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-35-9 CAPLUS

CN 3-Pyridinecarboxamide, 4-(3,4-dichlorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-36-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-37-1 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo-4-(3-quinolinyl)- (CA INDEX NAME)



RN 864082-38-2 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-fluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-1,2-dimethyl-6-oxo- (CA INDEX NAME)



RN 864082-40-6 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/589,995




RN 864082-41-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-42-8 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)



RN 864082-43-9 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-44-0 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-45-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-46-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-ethyl-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-47-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-48-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-50-8 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-2-methyl-N-(7-methyl-1H-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864082-51-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-54-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-55-3 CAPLUS

CN 3-Pyridinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864082-56-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-ethyl-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-57-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-58-6 CAPLUS


CN 3-Pyridinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-N-(7-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-59-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-60-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864082-61-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-62-2 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(3-ethyl-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-63-3 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-64-4 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-2-methyl-N-(7-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-65-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(7-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-66-6 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)



RN 864082-67-7 CAPLUS


CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-68-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-ethyl-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)



RN 864082-69-9 CAPLUS


CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-2-methyl-N-(7-methyl-1H-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)



RN 864082-70-2 CAPLUS


CN 3-Pyridinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-(2-naphthalenyl)-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-71-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-74-6 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-75-7 CAPLUS


CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-N-1H-indazol-5-yl-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/589,995




RN 864082-78-0 CAPLUS

CN 3-Pyridinecarboxamide, 1,4,5,6-tetrahydro-4-(3-hydroxyphenyl)-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-79-1 CAPLUS

CN 3-Pyridinecarboxamide, 4-[4-(aminosulfonyl)phenyl]-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-80-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864082-81-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)



RN 864082-84-8 CAPLUS


CN 3-Pyridinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)



RN 864082-85-9 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-86-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864082-89-3 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)




RN 864082-90-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)




RN 864082-91-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864082-92-8 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-93-9 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chlorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-94-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)



RN 864082-95-1 CAPLUS


CN 3-Pyridinecarboxamide, N-(6-chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864082-96-2 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-1,2-dimethyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864082-99-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-1,2-dimethyl-6-oxo- (CA INDEX NAME)



RN 864083-00-1 CAPLUS


CN 3-Pyridinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-1,2-dimethyl-6-oxo- (CA INDEX NAME)



RN 864083-01-2 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/589,995




RN 864083-02-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864083-03-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)




RN 864083-04-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chlorophenyl)-1,4,5,6-tetrahydro-1,2-dimethyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864083-05-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(2-fluoro-5-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-07-8 CAPLUS


CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(2-fluoro-3-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-08-9 CAPLUS


CN 3-Pyridinecarboxamide, 4-(2-fluoro-5-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864083-09-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(2-fluoro-3-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-10-3 CAPLUS


CN 3-Pyridinecarboxamide, 4-[5-(aminosulfonyl)-4-chloro-2-fluorophenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-13-6 CAPLUS


CN 3-Pyridinecarboxamide, 4-[3-(aminosulfonyl)-4-chlorophenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864083-14-7 CAPLUS

CN 3-Pyridinecarboxamide, 4-[3-(aminosulfonyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-15-8 CAPLUS


CN 3-Pyridinecarboxamide, 4-(2,3-difluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)



RN 864083-18-1 CAPLUS


CN 3-Pyridinecarboxamide, 4-(2,3-difluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)

10/589,995




RN 864083-19-2 CAPLUS

CN 3-Pyridinecarboxamide, 4-(2,4-difluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-20-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-(2,4-difluorophenyl)-1,4,5,6-tetrahydro-N-1H-indazol-5-yl-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-21-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-4-(3-hydroxyphenyl)-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-22-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-[3-[(methanesulfonyl)amino]phenyl]-6-oxo- (CA INDEX NAME)




RN 864083-23-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-nitrophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-25-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(3-amino-4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-26-1 CAPLUS

CN 3-Pyridinecarboxamide, 4-[4-chloro-3-[(methylsulfonyl)amino]phenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-27-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-[3-nitro-4-(trifluoromethyl)phenyl]-6-oxo- (CA INDEX NAME)




RN 864083-30-7 CAPLUS

CN 3-Pyridinecarboxamide, 4-[3-amino-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-31-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-4-[3-[(methylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-6-oxo- (CA INDEX NAME)




RN 864083-32-9 CAPLUS

CN 3-Pyridinecarboxamide, 4-[3-[(ethylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-33-0 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(2-fluoro-5-nitrophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-34-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[4-fluoro-3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-35-2 CAPLUS

CN 3-Pyridinecarboxamide, 4-[2,3-difluoro-4-(trifluoromethyl)phenyl]-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-36-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-37-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-38-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-[1,1'-biphenyl]-4-yl-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-39-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(2-thienyl)phenyl]- (CA INDEX NAME)




RN 864083-40-9 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-bromophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-41-0 CAPLUS

CN 3-Pyridinecarboxamide, 4-(5-cyano-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-42-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(2-fluoro-4-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-43-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-(4-chloro-3-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-46-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-4-(4-chloro-3-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-47-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-methoxyphenyl)-1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864083-48-7 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-methoxyphenyl)-N-(3-ethyl-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-49-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-methoxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-50-1 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-methoxyphenyl)-N-(3-chloro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-51-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-4-(4-chloro-3-hydroxyphenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-52-3 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-hydroxyphenyl)-1,4,5,6-tetrahydro-2-methyl-N-(3-methyl-1H-indazol-5-yl)-6-oxo- (CA INDEX NAME)




RN 864083-53-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-hydroxyphenyl)-N-(3-ethyl-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-54-5 CAPLUS

CN 3-Pyridinecarboxamide, 4-(4-chloro-3-hydroxyphenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo- (CA INDEX NAME)




RN 864083-55-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-1,4,5,6-tetrahydro-1,2-dimethyl-6-oxo- (CA INDEX NAME)




RN 864083-56-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-1-[(3-methoxyphenyl)methyl]-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864083-59-0 CAPLUS

CN 3-Pyridinecarboxamide, 1-ethyl-N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864083-62-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-1-(2-methylpropyl)-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864083-65-8 CAPLUS

CN 1(4H)-Pyridineacetamide, 3-[[[6-fluoro-1H-indazol-5-yl]amino]carbonyl]-5,6-dihydro-N,N,2-trimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2003:972059 CAPLUS

DOCUMENT NUMBER: 140:27819

TITLE: Preparation of pyrazole derivatives as JNK inhibitors
 INVENTOR(S): Ohi, Norihito; Sato, Nobuaki; Soejima, Motohiro; Doko, Takashi; Terauchi, Taro; Naoe, Yoshimitsu; Motoki, Takafumi

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 561 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101968	A1	20031211	WO 2003-JP6777	20030529
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2482838	A1	20031211	CA 2003-2482838	20030529
AU 2003241925	A1	20031219	AU 2003-241925	20030529
EP 1510516	A1	20050302	EP 2003-733170	20030529
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1656079	A	20050817	CN 2003-812475	20030529
US 20050208582	A1	20050922	US 2003-447948	20030530
US 20050261339	A1	20051124	US 2005-509795	20050225
PRIORITY APPLN. INFO.:			JP 2002-158467	A 20020531
			JP 2003-153	A 20030106
			WO 2003-JP6777	W 20030529

OTHER SOURCE(S): MARPAT 140:27819

GI



AB The title compds. I [R1 represents (CO)h(NRa)j(CRb:CRc)kAr (wherein Ra, Rb, and Rc each independently represents hydrogen, halogeno, hydroxy, optionally substituted C1-6 alkyl, etc.); Ar = (un)substituted aromatic heterocyclic ring, etc.; h, j, k = 0 or 1; Cy is a 5- or 6-membered aromatic heterocycle; and V represents L-X-Y (wherein L is a single bond, optionally substituted C1-6 alkylene, etc.; X is a single bond, O, CO, etc.; and Y is hydrogen, halogeno, nitro, etc.); n = 0 - 4] are prepared Compds. of this invention in vitro showed IC50 values of 63 nM to 578 nM against JNK-3.

IT 633329-63-2P 633329-67-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as JNK inhibitors)

RN 633329-63-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-2,6-dimethoxy- (CA INDEX NAME)

Double bond geometry as shown.




RN 633329-67-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,6-dihydro-6-oxo- (CA INDEX NAME)

Double bond geometry as shown.

10/589,995



REFERENCE COUNT:

57

THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>